DSM sells 65% stake in caprolactam, acrylonitrile and composite resins businesses to CVC

10:24 AM | March 16, 2015 | Deepti Ramesh

The enterprise value of the transaction is €600 million ($674.8 million) plus an earnout of up to €175 million. Net cash proceeds at closing to DSM will be about €300–350 million.